Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

MicroRNAs (miRNAs) are small, noncoding RNAs which can bind to target mRNAs and regulate gene expression. Increasing evidences suggest that miRNAs play an important role in driving hepatocellular carcinoma (HCC) progression by regulating tumor cell proliferation, apoptosis, invasion, and migration. In this study, we demonstrated that the expression of microRNA-30a-3p (miR-30a-3p) was reduced in HCC cell lines in comparison to immortalized liver cell line, LO2. Augmented miR-30a-3p level markedly inhibited MHCC-97H cell growth, migration and invasion . MiR-30a-3p was also found to inhibit tumor growth using tumor-bearing mice. Mechanismly, was discovered to be a direct and functional target of miR-30a-3p in MHCC-97H cells. Raised miR-30a-3p expression reduced the transcriptional level of in MHCC-97H cells, while genetically upregulated expression was able to reverse the function of miR-30a-3p-mediated suppression of MHCC-97H cells growth, migration and invasion. In addition, we found that using a COX-2 inhibitor, celecoxib, could enhance the anti-metastatic role of miR-30a-3p in MHCC-97H cells. Lastly, we found that decreased COX-2 protein level affected PGE2 production, leading to lower Bcl-2, Caspase-3, MMP2 and MMP9 expression but higher Bax and E-cadherin expression, which in turn culminated in higher rates of cell death and lower rates of cell migration. Taken together, our findings demonstrate that miR-30a-3p could be a target for the treatment of hepatocellular carcinoma cells progression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176251PMC
http://dx.doi.org/10.7150/jca.52298DOI Listing

Publication Analysis

Top Keywords

mhcc-97h cells
16
hepatocellular carcinoma
12
carcinoma cells
8
growth migration
8
migration invasion
8
mir-30a-3p mhcc-97h
8
rates cell
8
mir-30a-3p
7
mhcc-97h
6
cells
6

Similar Publications

Objective: Dipeptidyl peptidase 9 (DPP9) not only regulates tumor progression and drug sensitivity, but also modifies oxidative stress mediated ferroptosis. This study aimed to investigate the effect of DPP9 inhibition on sorafenib sensitivity and its interaction with ferroptosis in hepatocellular carcinoma (HCC).

Methods: Two HCC cell lines (Huh7 and MHCC-97H) were transfected with DPP9 siRNA, followed by detection of reactive oxygen species (ROS), ferrous iron (Fe), malondialdehyde (MDA), and ferroptosis-related proteins, and treated by 0-16 μM sorafenib to calculate half-maximal inhibitory concentration (IC) for sensitivity assessment.

View Article and Find Full Text PDF

Three new arthrichitin derivatives I-K (-) and three known congeners (-) were isolated from a coculture of mangrove-derived fungi sp. and sp. using H NMR-guided fractionation.

View Article and Find Full Text PDF

Human cytochrome P450 1B1 (hCYP1B1), a heme-dependent monooxygenase predominantly expressed in extrahepatic tissues, has gained prominence as a critical therapeutic target for overcoming chemotherapy resistance and suppressing tumorigenesis. To explore potential inhibitors of hCYP1B1, three series of azepinoindole derivatives were rationally designed, synthesized, and biologically evaluated in this study. Primary structure-activity relationship (SAR) studies revealed that introducing a para-nitro group (p-NO) on the C-ring enhanced anti-hCYP1B1 activity, and 15n (half-maximal inhibitory concentration [IC] = 1.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) ranks among the top three causes of cancer-related mortality globally and is associated with a relatively low five-year overall survival rate. Naringenin has demonstrated significant inhibitory effects on various neoplasms; however, the mechanisms of action and potential molecular targets of naringenin in the context of HCC remain to be elucidated. Cellular proliferation in cancer cells was quantified using the Cell Counting Kit-8 (CCK-8) assay.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) ranks among the most prevalent and lethal cancers affecting humans. Currently, there are limited effective treatments available for HCC. Carfilzomib, a proteasome inhibitor, is known to exert anti-HCC activities; however, its underlying mechanisms of action remain unclear.

View Article and Find Full Text PDF